Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | AR | P10275 | 9/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617778 | 1.00 | PRKAA2 (0.42) | PRKAA2IDESMN1; SMN2RETAR | |
| SCHEMBL2120388 | 1.00 | PRKAA2 (0.42) | PRKAA2IDESMN1; SMN2RETAR | |
| SCHEMBL2617832 | 0.91 | SMN1; SMN2 (0.51) | PRKAA2IDESMN1; SMN2RETAR | |
| SCHEMBL2120603 | 0.91 | AR (0.50) | PRKAA2IDESMN1; SMN2ARTIPARP | |
| SCHEMBL2617834 | 0.91 | AR (0.50) | PRKAA2IDESMN1; SMN2ARTIPARP | |
| SCHEMBL2617777 | 0.91 | SMN1; SMN2 (0.51) | PRKAA2IDESMN1; SMN2RETAR | |
| SCHEMBL2120802 | 0.91 | SMN1; SMN2 (0.51) | PRKAA2IDESMN1; SMN2RETAR | |
| SCHEMBL2119470 | 0.91 | RET (0.41) | PRKAA2RETAR | |
| SCHEMBL2617867 | 0.91 | RET (0.41) | PRKAA2RETAR | |
| SCHEMBL2617801 | 0.91 | RET (0.41) | PRKAA2RETAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | PRKAA2 4495/4885IDE 1072/4885SMN1; SMN2 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.